Novel therapy for nasopharyngeal carcinoma - Where are we

Oral Oncology

Volumn 50, Issue 9, 2014, Pages 798-801

  Tsang, Janice ^a   Lee, Victor H F ^a   Kwong, Dora L W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Immunotherapy; Nasopharyngeal carcinoma; Novel therapy; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR; VIRUS ANTIGEN; VASCULOTROPIN A;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER THERAPY; EPSTEIN BARR VIRUS; HUMAN; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SYSTEMIC THERAPY; TRANSLATIONAL RESEARCH; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; METABOLISM; NASOPHARYNGEAL NEOPLASMS;

HUMANS; IMMUNOTHERAPY; NASOPHARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905917069     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.01.002     Document Type: Article

References (57)

1. L. Barnes, J.W. Eveson, P. Reichart, and D. Sidransky Pathology and genetics of head and neck tumours 2005 IARC Press Lyon, France
2. W.I. Wei, and J.S. Sham Nasopharyngeal carcinoma Lancet 365 2005 2041
3. A.W. Lee, W.M. Sze, J.S. Au, S.F. Leung, T.W. Leung, and D.T. Chua et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience Int J Radiat Oncol Bio Phys 61 2005 1107 1116
4. H. Ali, and M. Al-Sarraf Chemotherapy in advanced nasopharyngeal cancer Oncology (Williston Park) 14 2000 1223 1230 [discussion 1232-1237, 1239-1242]
5. E.E. Vokes, D.N. Liebowitz, and R.R. Weichselbaum Nasopharyngeal carcinoma Lancet 350 1997 1087 1091
6. Y. Bensouda, W. Kaikani, N. Ahbeddou, R. Rahhali, M. Jabri, and H. Mrabti et al. Treatment for metastatic nasopharyngeal carcinoma Eur Ann Otorhinolaryngol Head Neck Dis 128 2011 79 85
7. F. Caponigro, F. Longo, F. Ionna, and F. Perri Treatment approaches to nasopharyngeal carcinoma: a review Anticancer Drugs 21 2010 471 477
8. B.B. Ma, and A.T. Chan Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma Expert Rev Anti-cancer Ther 6 2006 383 394
9. D.T. Chua, W.I. Wei, M.P. Wong, J.S. Sham, J. Nicholls, and G.K. Au Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma Head Neck 30 2008 863 867
10. B. Ma, E.P. Hui, and A. King et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy Cancer Chemother Pharmacol 62 2008 59 64
11. C. Elser, L.L. Siu, and E. Winquist et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 2007 3766 3773
12. W.T. Lim, Q.S. Ng, and P. Ivy et al. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma Clin Cancer Res 17 2011 5481 5489
13. E.P. Hui, B.B. Ma, and A.D. King et al. Haemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation Ann Oncol 22 2011 1280 1287
14. B. You, C. Le Tourneau, and E.X. Chen et al. A phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma Am J Clin Oncol 35 2012 255 260
15. A.T. Chan, M.M. Hsu, and B.C. Goh et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma J Clin Oncol 23 2005 3568 3576
16. Xue Cong, Yu Qitao, Pan Jian-ji, Sun Yuanlu, and Zhang Li A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma J Ciln Oncol 2012 30 [Suppl. abstr 5538]
17. D.T. Chua, J.M. Nicholls, J.S. Sham, and G.K. Au Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy Int J Radiat Oncol Biol Phys 59 2004 11 20
18. B. Ma, T. Poon, and K.F. To et al. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma Head Neck 25 2003 864 872
19. A.B. Hui, K.W. Lo, and P.M. Teo et al. Genomic wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization Int J Oncol 20 2002 467 473
20. B.B. Ma, S.F. Leung, and M.K. Kam et al. A phase II study of concurrent cetixumab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) J Clin Oncol 26 20 Suppl 2008 [abstract 6055]
21. S.L. Chan, and B.B. Ma Novel systemic therapeutic for nasopharyngeal carcinoma Expert Opin Ther Targets 16 Suppl 1 2012 Mar S63 S68
22. N. Ferrar Vascular endothelial growth factor Arterioscler Thromb Vasc Biol 29 2009 789 791
23. P.A. Kyzas, I.W. Cunha, and J.P. Ioannidis Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous carcinoma: a meta-analysis Ciln Cancer Res 11 2005 1434 1440
24. N. Wakisaka, Q.H. Wen, and T. Yoshizaki et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma Laryngoscope 109 1999 810 814
25. H. Guang-Wu, M. Sunagawa, and L. JieEn et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma Laryngoscope 110 2000 2066 2069
26. L. Rubio, J.S. Burgos, and C. Morera et al. Morphometric study of tumour angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients Pathol Oncol Res 6 2000 210 216
27. S. Murono, H. Inoue, and T. Tanabe et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells Proc Natl Acad Sci USA 98 2001 6905 6910
28. C.N. Qian, H.Q. Min, and H.L. Lin et al. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470) J Laryngol Otol 112 1998 849 853
29. C.N. Qian, H.Q. Min, and H.L. Lin et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HKI Oncology 57 1999 36 41
30. N.Y. Lee, Q. Zhang, D.G. Pfister, J. Kim, and A.S. Garden et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial Lancet Oncol 13 2 2012 172 180
31. E.P. Hui, V.W. Lui, and C.S. Wong et al. Preclinical evaluation of sunitinib as single-agent or in combination with chemotherapy in nasopharyngeal carcinoma Invest New Drugs 29 2011 1123 1131
32. C. Elser, L.L. Siu, and E. Winquist et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of head and neck or nasopharyngeal carcinoma J Clin Oncol 25 2007 3766 3773
33. W.T. Lim, C. Thng, and C.K. Toh et al. A phase II study of GW786034 (pazopanib) in Asia patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma J Clin Oncol 28 15S 2010 [abstract 5556]
34. Y. Cai, Q. Xia, Q. Su, R. Luo, and Y. Sun et al. MTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells Int J Mol Med 31 4 2013 904 912
35. B.B. Ma, V.W. Lui, E.P. Hui, and C.P. Lau et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines Invest New Drugs 28 4 2010 413 420
36. J. Kwong, K.W. Lo, and K.F. To et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma Clin Cancer Res 8 2002 131 137
37. S.L. Chan, Y. Cui, and A. van Hasselt et al. The tumour suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas Lab Invest 87 2007 644 650
38. K.F. Hui, D.N. Ho, C.M. Tsang, and J.M. Middeldorp et al. Activation of lytic cycle of Epstein-Barr virus bysuberoylanilide hydroxamic acid leads to apoptosis and tumour growth suppression of nasopharyngeal carcinoma Int J Cancer 131 8 2012 1930 1940 [October 15]
39. Phase I study of vorinostat (SAHA) and azacitidine in patients with locally recurrent or metastatic nasopharyngeal carcinoma or nasal type natural killer (NK)/T-cell lymphoma. Bethesda, MD: National Cancer Institute, 2006. NCT00336063.
40. A. Masmoudi, N. Toumi, A. Khanfir, and L. Kallel-Slimi et al. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma Cancer Treat Rev 33 2007 499 505
41. S. Gottschalk, H.E. Heslop, and C.M. Rooney Adoptive immunotherapy for EBV-associated malignancies Leuk Lymphoma 46 2005 1 10
42. C.M. Rooney, C.A. Smith, C.Y. Ng, S.K. Loftin, J.W. Sixbey, and Y. Gan et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients Blood 92 1998 1549 1955
43. R. Khanna, S. Bell, M. Sherritt, A. Galbraith, S.R. Burrows, and L. Rafter et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease Proc Natl Acad Sci USA 96 1999 10391 10396
44. T. Haque, G.M. Wilkie, M.M. Jones, C.D. Higgins, G. Urquhart, and P. Wingate et al. Allogeneic cytotoxic T-cell therapy for EBV-positive transplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial Blood 110 2007 1123 1131
45. P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, and M. Labirio et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes J Clin Oncol 23 2005 8942 8949
46. C.U. Louis, K. Straathof, C.M. Bollard, S. Ennamuri, C. Gerken, and T.T. Lopez et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma J Immunother 33 2010 983 990
47. K.C. Straathof, C.M. Bollard, U. Popat, M.H. Huls, T. Lopez, and M.C. Morriss et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes Blood 105 2005 1898 1904
48. L. Brooks, Q.Y. Yao, A.B. Rickinson, and L.S. Young Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts J Virol 66 1992 2689 2697
49. L.S. Young, C.W. Dawson, D. Clark, H. Rupani, P. Busson, and T. Tursz et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma J Gen Virol 69 1988 1051 1065
50. A.D. Hislop, G.S. Taylor, D. Sauce, and A.B. Rickinson Cellular responses to viral infection in humans: lesions from Epstein-Barr virus Annu Rev immunol 25 2007 587 617
51. C. Smith, L. Beagley, and R. Khanna Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression J Virol 83 2009 6192 6198
52. C. Smith, N. Wakisaka, T. Crough, J. Peet, T. Yoshizaki, and L. Beagley et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation Blood 113 2009 6148 6152
53. S.P. Lee, A.T. Chan, S.T. Cheung, W.A. Thomas, D. CrommoCarter, and C.W. Dawson et al. CTL control of EBV in nasopharyngeal carcinoma (MPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumour cells J Immunol 165 2000 573 582
54. C. Smith, J. Tsang, L. Beagley, D. Chua, V. Lee, and V. Li et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy Cancer Res 72 2012 1116 1125
55. V.P. Lutzky, M. Corban, L. Heslop, L.E. Morrison, P. Crooks, and D.F. Hall et al. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine J Virol 84 1 2010 Jan 407 417
56. W.K. Chia, W.W. Wang, M. Teo, W.M. Tai, W.T. Lim, and E.H. Tan et al. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1- LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma Ann Oncol 23 4 2012 997 1005
57. F. Li, D. Song, Y. Lu, H. Zhu, Z. Chen, and X. He Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy J Immunother 36 3 2013 Apr 208 214